Wire · opportunities
FDA panel supports broadening access to peptides popular on the gray market
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 July 2026 · Fusion42 review
An FDA advisory panel voted to recommend reclassifying six peptide therapies for compounding pharmacy production, overriding the agency's scientific objections and enabling legal domestic access to compounds currently sold only on unregulated markets. The move reflects political pressure from Health Secretary Kennedy and conflicts of interest on the newly stacked panel.
This Wire brief sits within Fusion42's coverage of Digital Health, and 12 sources have reported it between 22 Jul 2026 and 31 Jul 2026.
◆ ◆ The Wire takeaway
If the FDA accepts this recommendation, compounding pharmacies can now legally make and sell peptides that were only available through gray-market suppliers last month. You're watching a $2bn gray market turn white—whoever moves first into legitimate supply wins the customer base already buying unsafely.
◆ Coverage
12 sources · first reported 22 Jul 2026 · latest 31 Jul 2026
◆ Related on Wire
◆ Topics